KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $89.4 million.

  • CRISPR Therapeutics AG's Accumulated Expenses rose 11768.36% to $89.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $89.4 million, marking a year-over-year increase of 11768.36%. This contributed to the annual value of $89.4 million for FY2025, which is 11768.36% up from last year.
  • CRISPR Therapeutics AG's Accumulated Expenses amounted to $89.4 million in Q4 2025, which was up 11768.36% from $84.2 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Accumulated Expenses ranged from a high of $103.0 million in Q3 2022 and a low of $41.1 million during Q4 2024
  • For the 5-year period, CRISPR Therapeutics AG's Accumulated Expenses averaged around $74.4 million, with its median value being $77.1 million (2022).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Accumulated Expenses surged by 12744.02% in 2021, and later plummeted by 4164.03% in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Accumulated Expenses stood at $91.0 million in 2021, then dropped by 14.64% to $77.7 million in 2022, then tumbled by 41.64% to $45.3 million in 2023, then fell by 9.4% to $41.1 million in 2024, then soared by 117.68% to $89.4 million in 2025.
  • Its Accumulated Expenses was $89.4 million in Q4 2025, compared to $84.2 million in Q3 2025 and $73.7 million in Q2 2025.